Queensland Clinical Guidelines
Translating evidence into best clinical practice

Maternity and Neonatal Clinical Guideline

Hypoglycaemia—newborn
Well, at risk newborn baby (first 48 hours of life)

If baby is symptomatic for hypoglycaemia or screening BGL < 2.6 mmol/L–refer to Flowchart: Management of hypoglycaemic newborn baby

Risk factors for hypoglycaemia
- Temperature < 36.5 °C or labile
- Baby of woman with diabetes
- Preterm < 37 weeks gestation
- Inadequate feeding
- SGA < 10th centile
- LBW < 2500 g
- LGA > 90th centile
- Resuscitation at birth
- Post-mature baby > 42 weeks gestation
- Polycythemia
- Macrosomia
- Meconium aspiration syndrome
- Suspected syndromes
- Maternal medications–beta blockers; dexamethasone; oral hypoglycaemics
- Family history of metabolic and/or endocrine disorders

At birth
- Assess for risk factors
- Keep baby warm
  - Dry baby
  - Early skin-to-skin
  - Maintain temperature 36.5 °C–37.5 °C
  - Initiate feeds within 30–60 minutes of birth
  - Discuss feeding cues
  - Feed at least 3 hourly or more frequently
  - Gavage feed if baby < 35 weeks
- Keep mother and baby together if possible
  - Discuss preventative care with parents

Symptomatic or unwell baby
- May have one or more signs
  - Poor feeding
  - Tremors/jitteriness
  - Apnoea
  - Cyanosis
  - Irregular, rapid breathing
  - Seizures
  - Altered LOC–irritability, lethargy, stupor, coma
  - Hypotonia
  - Weak or high pitched cry

Effective 1st feed?
- Yes
- No

Ongoing care
- Keep baby warm
- Continue skin to skin contact
- Feed
  - Assist breast feeding mothers with attachment and hand expression
  - Give baby colostrum/EBM if available
  - Assist formula feeding baby
  - If concerned repeat BGL

BGL 2.6 mmol/L?
- Yes
  - Continue usual care
  - Cease BGL monitoring if:
    - BGL ≥ 2.6 mmol/L for 24 hours in 1st 48 hours or ≥ 3.3 after 48 hours
    - BGL for known hypoglycaemic disorder ≥ 4 mmol/L (after 6 hour fast test)
    - Baby feeding effectively and is well

BGL 1.5–2.5 mmol/L?
- Yes
- No

Confirm any BGL < 2.6 mmol/L in blood gas machine, PoC analyser or laboratory

If baby < 35 weeks and/or < 2500 g admit to neonatal unit and/or consult with RSQ

Confirm any BGL < 2.6 mmol/L

If baby < 35 weeks and/or < 2500 g admit to neonatal unit and/or consult with RSQ

If indicated/possible give glucose gel 40% and feed baby
- Medical/NNP review
- Admit to neonatal unit
- Refer to Flowchart: Initial management of hypoglycaemia in newborn baby–symptomatic or BGL < 1.5 mmol/L (first 48 hours of life)

If baby > 48 hours of age and BGL < 3.3 mmol/L manage as persistent hypoglycaemia
- Refer to Flowchart: Initial management of hypoglycaemic newborn baby (first 48 hours of life)
  - BGL 1.5 mmol/L–2.5 mmol/L

BGL blood glucose level, EBM expressed breast milk, IV intravenous, LBW low birth weight, LGA large for gestational age, LOC level of consciousness, NNP neonatal nurse practitioner, RSQ Retrieval Services Queensland, SGA small for gestational age, < less than, > greater than, ≥ greater than or equal to

Flowchart: F19.8-1-V7-R24
Flow Chart: Management of hypoglycaemic newborn baby (BGL 1.5–2.5 mmol/L)

Initial management of hypoglycaemic newborn baby (first 48 hours of life)
BGL 1.5 mmol/L–2.5 mmol/L

BGL 1.5–2.5 mmol/L?
  Yes → If BGL ≥ 2.6 mmol/L–usual care
  No → BGL < 1.5 or unrecordable or symptomatic baby?

If consent for formula withheld:
- Discuss benefits and risks of formula versus hypoglycaemia outcomes
- Consider IV glucose

BGL ≥ 2.6 mmol/L?
  Yes → Continue usual care
  No → Cease BGL monitoring if:
  - BGL ≥ 2.6 mmol/L for 24 hours in 1st 48 hours or ≥ 3.3 mmol/L after 48 hours
  - Baby feeding effectively—if term baby, enteral feeding discontinued
  - Baby is well and has not required IV glucose
- If known/suspected hypoglycaemic disorder:
  - Continue BGL monitoring and maintain ≥ 4 mmol/L and
  - Do 6 hour fast test
- Discharge and follow-up
  - As per underlying cause
  - May require long-term follow-up
  - May require 6 hour fast test prior to discharge

BGL ≥ 2.6 mmol/L?
  Yes → Monitor BGL 4–6 hourly pre-feed for 1st 24–48 hours
  No → BGL ≥ 2 mmol/L and meets glucose gel 40% criteria?

BGL ≥ 2.6 mmol/L and meets glucose gel 40% criteria?
  Yes → 2 doses glucose gel 40% with feed or BGL < 2 mmol/L?
    Yes → BGL ≥ 2.6 mmol/L?
      Yes → Confirm any BGL < 2.6 mmol/L in blood gas machine, PoC analyser or laboratory
      No → Volume to be administered

Glucose gel 40% (0.5 mL/kg)

<table>
<thead>
<tr>
<th>Baby's weight</th>
<th>Volume to be administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000–2080 g</td>
<td>1 mL</td>
</tr>
<tr>
<td>2081–2280 g</td>
<td>1.1 mL</td>
</tr>
<tr>
<td>2281–2480 g</td>
<td>1.2 mL</td>
</tr>
<tr>
<td>2481–2680 g</td>
<td>1.3 mL</td>
</tr>
<tr>
<td>2681–2880 g</td>
<td>1.4 mL</td>
</tr>
<tr>
<td>2881–3080 g</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>3081–3280 g</td>
<td>1.6 mL</td>
</tr>
<tr>
<td>3281–3480 g</td>
<td>1.7 mL</td>
</tr>
<tr>
<td>3481–3680 g</td>
<td>1.8 mL</td>
</tr>
<tr>
<td>3681–3880 g</td>
<td>1.9 mL</td>
</tr>
<tr>
<td>3881–4080 g</td>
<td>2.0 mL</td>
</tr>
<tr>
<td>4081–4280 g</td>
<td>2.1 mL</td>
</tr>
<tr>
<td>4281–4480 g</td>
<td>2.2 mL</td>
</tr>
<tr>
<td>4481–4680 g</td>
<td>2.3 mL</td>
</tr>
<tr>
<td>4681–4880 g</td>
<td>2.4 mL</td>
</tr>
<tr>
<td>4881–5080 g</td>
<td>2.5 mL</td>
</tr>
</tbody>
</table>

BGL blood glucose level, EBM expressed breast milk, IV intravenous, NNP neonatal nurse practitioner, < less than, ≥ greater than or equal to

Flowchart: F19.8-2-V6-R24
Flow Chart: Management of neonatal hypoglycaemia (baby symptomatic or BGL < 1.5 mmol/L)

**Initial management of hypoglycaemia in newborn baby—symptomatic or BGL < 1.5 mmol/L (first 48 hours of life)**

- Do not delay treatment
- Urgent medical review/consider neonatologist consultation
- Confirm BGL in blood gas machine, PoC analyser or laboratory
- Admit to neonatal unit—contact RSQ as required
- If indicated collect diagnostic samples for hypoglycaemia screen

### Urgent treatment

- Give glucagon—200 microgram/kg IV
  - If IV access delayed (>10 minutes) give IM or subcut
- Give glucose 10%—1—2 mL/kg bolus IV, then repeat BGL after 30 minutes and if required, further 1 mL/kg bolus IV and monitor for rebound hypoglycaemia
- Commence glucose 10% at 60 mL/kg/day via IV infusion to give glucose at 4.2 mg/kg/min

### As required

- Increase IV glucose rate in 20 mL/kg/day increments (e.g. 60 to 80 mL/kg/day)
  - Risk of fluid overload—100 mL/kg/day maximum on day 1 of life (monitor serum sodium levels)
- Increase IV glucose concentration to 12% or step-wise to higher concentration
  - If > 12% glucose administer by UVC/CVL
- If GIR > 8 mg/kg/min in 1st 24 hours or baby hyponatraemic consider glucagon infusion

### BGL

- Repeat 30 minutes after:
  - Commencing or any changes to glucose concentration
  - Medication administration (for hypoglycaemia)
  - Repeat hourly until ≥ 3 mmol/L then, 4–6 hourly
- Feeds—continue if not contraindicated

---

**Glucose mg/kg/minute**

<table>
<thead>
<tr>
<th>%</th>
<th>60</th>
<th>80</th>
<th>100</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>10%</td>
<td>4.2</td>
<td>5.6</td>
<td>6.9</td>
<td>8.3</td>
</tr>
<tr>
<td>12%</td>
<td>5</td>
<td>6.7</td>
<td>8.3</td>
<td>10</td>
</tr>
<tr>
<td>14%</td>
<td>5.8</td>
<td>7.8</td>
<td>9.7</td>
<td>11.7</td>
</tr>
<tr>
<td>16%</td>
<td>6.7</td>
<td>8.9</td>
<td>11.1</td>
<td>13.3</td>
</tr>
<tr>
<td>18%</td>
<td>7.5</td>
<td>10</td>
<td>12.5</td>
<td>15</td>
</tr>
<tr>
<td>20%</td>
<td>8.3</td>
<td>11</td>
<td>13.9</td>
<td>16.7</td>
</tr>
</tbody>
</table>

**Diagnostic samples**

**Blood**—during hypoglycaemic episode

| Blood glucose, haemoglobin, haematocrit and lactate
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority 1</td>
<td>Insulin</td>
<td>Cortisol</td>
<td>Acyl-carnitine profile</td>
</tr>
<tr>
<td>Priority 2</td>
<td>Growth hormone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority 3</td>
<td>Plasma amino acids</td>
<td>Ammonium</td>
<td>Pyruvate</td>
</tr>
</tbody>
</table>

**Urine**—post-hypoglycaemic episode

- Metabolic screen

**Discharge and follow-up**

- As per underlying cause
- May require long-term follow-up
- If baby has known or suspected hypoglycaemic disorder continue BGL monitoring until 6 hour fast test completed

---

**BGL** blood glucose level, **CVL** central venous line, **GIR** glucose infusion rate, **IM** intramuscular, **IV** intravenous, **NNP** neonatal nurse practitioner, **PoC** point of care, **RSQ** Retrieval Services Queensland, **subcut** subcutaneous, **UVC** umbilical venous catheter,

> greater than, < less than, ≥ greater than or equal to

---

Flowchart: F19.8-3-V6-R24
Table of Contents

Abbreviations .......................................................................................................................................................... 7
Definitions ................................................................................................................................................................. 7
1 Introduction .......................................................................................................................................................... 8
  1.1 Normal physiology ...................................................................................................................................... 8
  1.2 Definition .................................................................................................................................................... 9
2 Babies at risk ...................................................................................................................................................... 10
  2.1 Causes ...................................................................................................................................................... 10
  2.2 Maternal risk factors ................................................................................................................................. 10
  2.3 Baby risk factors and causes of hypoglycaemia .......................................................................................... 11
  2.3.1 Risk factors and causes ....................................................................................................................... 11
  2.3.2 Other causes ....................................................................................................................................... 12
3 Identification .................................................................................................................................................... 13
  3.1 Screening and assessment of at risk baby (asymptomatic) ....................................................................... 13
  3.2 Clinical signs ............................................................................................................................................ 14
4 Management ................................................................................................................................................... 15
  4.1 Prevention ............................................................................................................................................... 15
  4.2 Initial management (first 48 hours of life) ................................................................................................. 16
  4.3 Glucose gel 40% ..................................................................................................................................... 17
  4.3.1 Glucose gel doses ............................................................................................................................... 18
  4.4 Ongoing management ............................................................................................................................... 19
    4.4.1 BGL monitoring ................................................................................................................................. 19
    4.4.2 Other management ............................................................................................................................ 20
  4.5 Intravenous glucose .................................................................................................................................. 21
    4.5.1 Regimen for glucose infusion ........................................................................................................... 22
5 Medications ..................................................................................................................................................... 23
6 Persistent hypoglycaemia ............................................................................................................................... 24
  6.1 Further investigation and management ................................................................................................. 24
  6.2 Pathology tests ....................................................................................................................................... 25
  6.3 Interpretation of investigations .............................................................................................................. 26
  6.4 Long term management .......................................................................................................................... 26
  6.5 Six hour fast test .................................................................................................................................... 27
7 Sequelae of hypoglycaemia ........................................................................................................................... 28
8 Discharge planning ....................................................................................................................................... 29
References ............................................................................................................................................................ 30
Appendix A Growth charts examples .................................................................................................................. 32
Appendix B Glucose 40% gel doses ................................................................................................................... 34
Appendix C Glucose infusion rates (GIR) ............................................................................................................ 35
Appendix D Preparing glucose concentrations for infusion ............................................................................. 36
Appendix E Investigations for neonatal hypoglycaemia .................................................................................... 37
Acknowledgements ........................................................................................................................................... 38

List of Tables

Table 1. Clinical hypoglycaemia ............................................................................................................................. 9
Table 2. Maternal risk factors ............................................................................................................................ 10
Table 3. Risk factors and causes ....................................................................................................................... 11
Table 4. Congenital and other causes ............................................................................................................... 12
Table 5. Screening ............................................................................................................................................. 13
Table 6. Clinical signs ....................................................................................................................................... 14
Table 7. Prevention ......................................................................................................................................... 15
Table 8. Initial management (first 48 hours of life) ............................................................................................ 16
Table 9. Glucose gel ....................................................................................................................................... 17
Table 10. Glucose gel regimen ........................................................................................................................ 18
Table 11. BGL measurement ............................................................................................................................ 19
Table 12. Ongoing management ....................................................................................................................... 20
Table 13. IV fluids .......................................................................................................................................... 21
Table 14. Regimen for glucose infusion .......................................................................................................... 22
Table 15. Medications .................................................................................................................................... 23
Table 16. Indications for investigations ........................................................................................................... 24
Table 17. Tests .................................................................................................................................................. 25
Table 18. Investigations interpretation ............................................................................................................. 26
Table 19. Ongoing long term management ..................................................................................................... 26
Table 20. Six hour fast test ............................................................................................................................... 27
Table 21. Sequelae ......................................................................................................................................... 28
Table 22. Discharge planning ........................................................................................................................ 29
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGL</td>
<td>Blood glucose level</td>
</tr>
<tr>
<td>EBM</td>
<td>Expressed breast milk</td>
</tr>
<tr>
<td>FGR</td>
<td>Fetal growth restriction</td>
</tr>
<tr>
<td>GIR</td>
<td>Glucose infusion rate</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational diabetes mellitus</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LCHAD</td>
<td>Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>LGA</td>
<td>Large for gestational age (consider parental ethnicity and anthropometry)</td>
</tr>
<tr>
<td>MCADD</td>
<td>Medium chain acyl-CoA dehydrogenase deficiency</td>
</tr>
<tr>
<td>NICU</td>
<td>Neonatal intensive care unit</td>
</tr>
<tr>
<td>NNP</td>
<td>Neonatal nurse practitioner</td>
</tr>
<tr>
<td>PICC</td>
<td>Peripherally inserted catheter</td>
</tr>
<tr>
<td>RSQ</td>
<td>Retrieval Services Queensland</td>
</tr>
<tr>
<td>SGA</td>
<td>Small for gestational age (consider parental ethnicity and anthropometry)</td>
</tr>
<tr>
<td>UVC</td>
<td>Umbilical venous catheter</td>
</tr>
</tbody>
</table>

Definitions

<table>
<thead>
<tr>
<th>Clinical judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical significance</td>
<td>Conditions that raise higher concern if the blood glucose level (BGL) is borderline or at the lower end of the normal range and may require earlier intervention.</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>BGL less than 2.6 mmol/L</td>
</tr>
<tr>
<td>Hypoglycaemia–prolonged</td>
<td>Lasts longer than 48 hours</td>
</tr>
<tr>
<td>Hypoglycaemia–recurrent</td>
<td>More than 3 sequential episodes of BGL less than 2.6 mmol/L</td>
</tr>
<tr>
<td>Hypoglycaemia–severe</td>
<td>BGL less than 1.5 mmol/L or symptomatic</td>
</tr>
<tr>
<td>Macrosomia</td>
<td>Birth weight greater than the 90th percentile or intrauterine growth beyond 4.5 kg</td>
</tr>
<tr>
<td>Nadir</td>
<td>The lowest point, e.g. lowest blood glucose level</td>
</tr>
<tr>
<td>Neonatal Unit</td>
<td>Area for babies requiring care and management ranging from standard newborn care to special or intensive care. This may be an area of the maternity ward while waiting for Retrieval Services Queensland (RSQ).</td>
</tr>
</tbody>
</table>
1 Introduction

1.1 Normal physiology

During fetal life glucose, lactate and amino acids are the principal sources of energy. The fetus receives glucose from the mother achieving fetal plasma glucose concentrations 70–80% of the maternal level. The fetal insulin level is independent of the mother's level, as insulin does not cross the placenta, but it is dependent on the fetal blood glucose level. During the last trimester of pregnancy when there is rapid growth, energy stores (particularly glycogen and adipose tissue) are laid down in preparation for birth.3

Blood glucose levels (BGL) in healthy term newborn babies fall in the first two hours of life during transition to extra-uterine life. An asymptomatic, transient and mildly low BGL after birth is normal.4 It occurs due to the transition from continuous transplacental glucose supply from the mother in-utero, to an intermittent supply from milk feeds.

Physiological transition beginning immediately after birth includes—

- Endocrine changes—
  - Plasma insulin levels fall and catecholamines and pancreatic glucagon are released
  - Essential enzymes for the production of glucose from stores of glycogen and fat (glycogenolysis and gluconeogenesis), and the production of free fatty acids (lipolysis) and ketones (ketogenesis) are switched on3
  - Importantly, the production of these enzymes is inhibited by insulin, so persistent high insulin levels prevent this normal adaptation
- Glycogenolysis—production of glucose by the liver when stored glycogen is broken down to form pyruvate in response to increased adrenaline and glucagon concentrations and falling insulin levels3
- Gluconeogenesis—plasma glucose levels are maintained by glucose synthesis from non-carbohydrate sources, e.g. glycerol, lactate, pyruvate and glucogenic amino acid precursors and occurs during the first 8–12 hours of life when glycogen stores are depleted3,5
- Stimulation of appetite and adaption to fast and feed cycle and promotion of oxidative fat metabolism using lipid from fat stores and milk feeds5
  - Delay in the first feed for 3–6 hours after birth results in approximately 10% of babies not maintaining their plasma glucose levels above 1.7 mmol/L6
  - Concentrations of free fatty acids, lactate and ketones as substrate for metabolism are raised in response to breast feeding

It is generally accepted that the BGL is low in the first six hours of life. However, there is lack of international consensus about the normal range for prefeed plasma glucose in the normal healthy baby during this time period. The nadir usually falls in the first two to four hours of life then, by four to six hours of age stabilises at 2.5–4.4 mmol/L (may be up to 6.2 mmol/L).5 Over subsequent days the mean BGL rises slowly to concentrations seen in older children and adults6, and is generally acceptable if above 3.6 mmol/L without any treatment in place.

Glucose levels in the blood are maintained during post-prandial and post-absorptive states by balancing glucose utilisation with endogenous glucose production. Counter-regulation is the process in the fasted state where the body makes glucose available.3 Due to the disproportionately larger brain size relative to body mass, babies' glucose utilisation rate (per unit of body mass) is two to three times higher compared with adults.4

This normal physiological transitional response is different from disorders resulting in persistent or recurrent hypoglycaemia.7
### 1.2 Definition

#### Table 1. Clinical hypoglycaemia

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Context**                         | - A baby’s BGL changes in the first hours after birth  
- Generally, hypoglycaemia is defined as:  
  o Symptomatic baby [refer to Table 6. Clinical signs] and/or  
  o BGL less than 2.6 mmol/L\(^8^-^1^0\)  
    - If BGL less than 1.5 mmol/L or unrecordable–hypoglycaemia is severe |
| **Clinical hypoglycaemia**          | - BGL low enough to cause signs of impaired brain function\(^1^1\) [refer to Table 6. Clinical signs]  
- Not defined based on specific BGL\(^1^1\) as:  
  o Not possible to identify single BGL that causes brain injury  
    - Injury extent influenced by other factors including extent and duration of hypoglycaemia, and availability and baby’s ability to use other substrates such as lactate, fatty acids and ketones  
  o Specific brain response thresholds to hypoglycaemia vary across different BGL |
| **Factors influencing clinical significance** | - Inborn errors of metabolism  
- Hyponatraemia  
- Neonatal encephalopathy  
- Conditions associated with diminished hepatic glucose production\(^1^2\) or increased glucose consumption  
  o Cold stress  
  o Congenital heart disease; congestive heart failure  
  o Intrauterine growth restriction  
  o Prematurity  
  o Perinatal stress/hypoxia  
  o Sepsis/infection |
| **Clinical standards**              | - Screen all at risk babies  
- Avoid separation of mother and baby unless admission to neonatal unit is required for investigation and management  
- Screen baby with glucometer with electrochemical sensor that uses glucose oxidase test strips\(^1^3\)  
- Refer to Queensland Clinical Guideline Standard care\(^1^4\) |
| **Blood sample collection**        | - Use heel prick (do not squeeze poorly perfused heel) or venepuncture for screening  
- If taking heel prick sample, warm the baby’s heel and discard the first drop of blood to optimise accuracy in glucometer reading  
- Use venepuncture for diagnostic tests (including BGL when indicated)  
- Do not take samples from intravenous or intra-arterial lines infusing glucose  
- Ensure adequate drawback of fluid and blood from indwelling lines administering other solutions, for example sodium chloride 0.9\% |
2 Babies at risk

2.1 Causes

Generally, neonatal hypoglycaemia is caused by one or more of:

- Increased levels of insulin (regulatory hormone)\(^3,12,15-18\)
- Increased glucose utilisation\(^12\)
- Inadequate glucose supply\(^3,12\)
- Inadequate body stores (glycogen, fat)\(^18-20\)
- Decreased levels of counter-regulatory hormones (e.g. growth hormones, cortisol, adrenergic hormones)\(^12,15,17,18\)
- Disorders of glycogen metabolism (glycogenolysis)\(^12,16,20\)
- Disorders of glucose production (gluconeogenesis)\(^12,16,19,20\)
- Congenital anomalies, or unknown or mixed causes\(^3-6,15,16,21,22\)

Babies at risk may or may not present with signs of hypoglycaemia [refer to Table 6. Clinical signs]. The number and type of risk factors need to be considered when planning the management for the baby. Extra vigilance is required for babies who have multiple risk factors. These include babies born to women with diabetes mellitus (any type) or if there is a sibling or other family member with a history of a metabolic disorder such as medium chain acyl-CoA dehydrogenase deficiency (MCADD) or an endocrine disorder (e.g. adrenal or pituitary).

Where there is impaired metabolic adaptation there may be impaired glucose and ketone body production. This may be due to various conditions including preterm babies, intrauterine growth restriction, perinatal hypoxia/ischaemia and poorly controlled GDM–refer to Table 2. Maternal risk factors and Table 3. Risk factors and causes. These babies require prevention, diagnosis and management of hypoglycaemia to reduce the risk of harm.\(^3\)

2.2 Maternal risk factors

Table 2. Maternal risk factors

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal medications</td>
<td>• Beta-blockers(^6,23) (aOR 1.68, 95% CI 1.50–1.89)(^23), e.g. propranolol, atenolol, labetalol&lt;br&gt;• Oral hypoglycaemic agents(^6) given for non-diabetes conditions such as polycystic ovarian syndrome (e.g. metformin)&lt;br&gt;• Maternal antenatal betamethasone(^25-27) may cause transient fetal adrenal suppression if administered to women after 36 weeks gestation within 24 hours of birth(^28) or multiple courses&lt;br&gt;• Terbutaline as tocolysis within previous 48 hours(^6,29)</td>
</tr>
<tr>
<td>Maternal diabetes</td>
<td>• Any type of diabetes mellitus–especially if there is poor control and/or a macrosomic baby&lt;br&gt;• Maternal diabetes control rather than type or treatment (diet, oral hypoglycaemic medicines or insulin) of diabetes is the important factor(^16,30,31)</td>
</tr>
<tr>
<td>Known family history</td>
<td>• Family history of genetic form of hypoglycaemia(^4,6,19) or congenital hyperinsulinaemic disorder or endocrine disorder (e.g. adrenal or pituitary)&lt;br&gt;• Sibling or parent of baby with:&lt;br&gt;  o MCADD&lt;br&gt;  o Other fatty acid oxidation defect, e.g. long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)</td>
</tr>
<tr>
<td>Intrapartum intravenous (IV) glucose</td>
<td>• IV glucose administration greater than 20 g/hour causing transient hyperinsulinaemia (e.g. Hartmann’s solution with glucose 5% at greater than 400 mL/hour or glucose 10% at greater than 200 mL/hour)</td>
</tr>
<tr>
<td>Maternal conditions</td>
<td>• Maternal pre-eclampsia/eclampsia or hypertension or other conditions causing placental insufficiency from any cause(^4,15)</td>
</tr>
</tbody>
</table>
## 2.3 Baby risk factors and causes of hypoglycaemia
Some risk factors such as fetal growth restriction (FGR) predispose a baby to hypoglycaemia through several mechanisms.

### 2.3.1 Risk factors and causes

**Table 3. Risk factors and causes**

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Increased glucose utilisation** | - Increased glucose requirements:  
  o Temperature less than 36.5 °C\(^4,12,15,19,32\) or labile  
  o Perinatal/birth asphyxia–acidosis (e.g. cord pH less than 7.0, base deficit less than 12 mmol/L); need for prolonged resuscitation\(^4,6,16,19\)  
  o Infection\(^3\)  
  o Congenital heart disease  
  o Respiratory disease  
  o FGR–less than 2500 g at term gestation or less than 10th centile\(^4,15,18\)—use clinical judgement considering factors such as the baby’s appearance, and the parental ethnicity and anthropometry and refer to growth charts, e.g. Appendix A Growth charts  
  o Polycythaemia/hyperviscosity\(^4,6,15\)  
  o Seizures\(^19\)  |
| **Inadequate glucose supply** | - Delayed or inadequate feeding\(^6\)  
  - IV therapy–abrupt cessation or rapid weaning of glucose infusion including infusion infiltration in baby  |
| **Inadequate body stores** | - Inadequate substrate stores or ability to use  
  - FGR–baby may or may not be small for gestational age (SGA); weight less than 2500 g at term gestation or less than 10th centile\(^16,20\)—use clinical judgement considering factors such as the baby’s appearance, and the parental ethnicity and anthropometry  
  o Refer to locally endorsed growth charts or Fenton growth charts [refer to Appendix A Growth charts  
  o Gestation–preterm\(^3,12\) (less than 37+0 weeks gestation)\(^6,16\) or post-mature (more than 42+0 weeks gestation)\(^6\) or earlier if there is placental insufficiency  
  o Maternal use of beta-blockers\(^23\) or terbutaline\(^6\)  
  o Severe hepatic dysfunction  |
| **Increased levels of insulin** | - Maternal diabetes\(^3,4,6,12,15,20\)  
  - Intrapartum maternal administration of IV glucose greater than 20 g/hour\(^16\)  
  - Large for gestational age (LGA)\(^15,18\); FGR\(^4,6,15\)  
  o Refer to Appendix A Growth charts (example charts)  
  - Hyperinsulinaemia\(^18\)  
  o Persistent neonatal hyperinsulinaemic hypoglycaemia\(^20\);  
  o Leucine sensitivity  
  o Insulinoma (rare)  
  o Beckwith-Wiedemann Syndrome\(^16,20\); Kabuki syndrome\(^22\)  
  o Perinatal asphyxia or hypoxic stress\(^4,6,15\)  
  o Erythroblastosis\(^16\), (e. g. haemolytic disease of the newborn\(^3,8\))  
  o Iatrogenic—from erroneous or malicious administration of insulin\(^3\)  |
| **Decreased levels of counter-regulatory hormones** | - Impaired glucose homeostasis from endocrine disorders:  
  o Multiple pituitary hormone deficiency\(^18\) including panhypopituitarism  
  o Adrenocorticotropic hormone (ACTH) deficiency\(^6\)  
  o Growth hormone deficiency\(^18\)  
  o Primary adrenal dysfunction (haemorrhage, congenital adrenal hyperplasia)  
  - Other syndromes and endocrine disorders that cause pituitary dysfunction:  
  o Suspect if midline defects—facial anomalies, micropenis, midline brain anomalies—detected antenatally (e.g. absent septum pellucidum, absent corpus callosum)  |
2.3.2 Other causes

Table 4. Congenital and other causes

<table>
<thead>
<tr>
<th>Congenital anomalies</th>
<th>Beckwith-Wiedemann syndrome/exomphalos\textsuperscript{3,4,16,21}, Kabuki syndrome\textsuperscript{22}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Other major congenital anomalies or congenital anomaly syndromes\textsuperscript{15,16}</td>
</tr>
<tr>
<td>Disorders of glycogenolysis</td>
<td>Inborn errors of carbohydrate metabolism\textsuperscript{16,18,20}</td>
</tr>
<tr>
<td></td>
<td>- Glycogen storage disease types 1 (von Gierke’s), III and IV</td>
</tr>
<tr>
<td>Disorders of gluconeogenesis</td>
<td>Inborn errors of carbohydrate metabolism\textsuperscript{16,18,20}, (e.g. galactosaemia)</td>
</tr>
<tr>
<td></td>
<td>Inborn errors of amino acid metabolism\textsuperscript{16,18,20}, (e.g. maple syrup urine disease; propionicidaemia; methylmalonicacidaemia)</td>
</tr>
<tr>
<td></td>
<td>Inborn errors of fatty acid oxidation\textsuperscript{18,33}, (e.g. MCADD, LCHAD)</td>
</tr>
<tr>
<td>Unknown or mixed causes</td>
<td>Hypothyroidism\textsuperscript{24}</td>
</tr>
<tr>
<td></td>
<td>Meconium aspiration syndrome\textsuperscript{4,6,15}</td>
</tr>
</tbody>
</table>
3 Identification

3.1 Screening and assessment of at risk baby (asymptomatic)

- If the baby is symptomatic [refer to Table 6. Clinical signs], they require blood tests and intervention to manage their hypoglycaemia. Refer to Table 8. Initial management
- Target BGL in this section refers to babies in their first 48 hours of life. Refer also to Section 6 Persistent hypoglycaemia
- Poor sampling techniques (venepuncture or capillary) may provide inaccurate results—refer to local protocols and education regarding correct techniques and use of equipment.

Table 5. Screening

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Physical assessment<sup>6,30,34</sup> | - Identify if baby is:  
  o LGA—greater than 90th centile or greater than 4500 g<sup>19,20</sup>  
  o SGA<sup>19,20</sup> less than 2500 g at term gestation or less than 10th centile  
  ▪ Refer to Appendix A Growth charts for example growth charts  
  o Antenatal evidence (ultrasound) of intrauterine growth restriction, even if greater than 10th centile  
  - Undertake complete physical assessment to identify signs associated with neonatal hypoglycaemia  
  - Refer to Table 6. Clinical signs  
  - Refer to Queensland Clinical Guideline Routine newborn assessment<sup>35</sup> |
| BGL screening asymptomatic baby | - Screening times:  
  o 1st BGL before second feed and not later than three hours of age<sup>3</sup>  
  o 2nd BGL screen before third feed and not later than six hours of age  
  o If normal (greater than or equal to 2.6 mmol/L) screen before every second feed—every three to six hours pre-feed for 24 hours depending on feeding frequency  
  - Screen baby who has risk factors:  
  o Refer to Table 2. Maternal risk factors, Table 3. Risk factors and causes and Other causes  
  o Table 4. Congenital and other causes |
| BGL screening | - Provide adequate pain relief to baby for blood sampling according to local protocols, (e.g. oral sucrose or breastfeeding)  
  - Capillary blood may be used for screening  
  - If available, use point of care glucometer that uses glucose oxidase or glucose dehydrogenase methodology  
  o Otherwise, use a calibrated non-enzymatic glucometer with electrochemical sensor that has been validated for neonatal samples  
  o Non-enzymatic glucometers may be unreliable at lower BGLs  
  - If screening BGL by glucometer is less than 2.6 mmol/L, or is a borderline result in a baby with significant risk factors or clinical signs of hypoglycaemia<sup>36</sup>:  
  o Validate by diagnostic test using point of care analyser (not non-enzymatic glucometer), blood gas analyser or laboratory specimen in fluoride oxalate tube—if feasible and can be accomplished promptly  
  o Do not delay treatment, especially if hypoglycaemia is persistent or recurrent, BGL is less than 2 mmol/L or baby is symptomatic  
  - If glucometer BGL is less than or equal to 2 mmol/L, confirmation by a validated diagnostic testing method is recommended  
  - If validated BGL less than 2.6 mmol/L, refer to Table 8. Initial management  
  - Refer to local protocols for correct sampling technique |
3.2 Clinical signs
Hypoglycaemia can be asymptomatic. Measure the BGL and consider the clinical signs in the differential diagnosis. Clinical signs may overlap or be concurrent with other newborn disorders.

Table 6. Clinical signs

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurogenic(^\text{18})</td>
<td>• Jitteriness(^\text{12}) or persistent tremor(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Breathing–irregular and rapid</td>
</tr>
<tr>
<td></td>
<td>• Sweating</td>
</tr>
<tr>
<td></td>
<td>• Irritability</td>
</tr>
<tr>
<td></td>
<td>• Pallor</td>
</tr>
<tr>
<td>Neuroglycopenic(^\text{18})</td>
<td>• If neurological signs present, this may represent severe hypoglycaemia(^\text{6})</td>
</tr>
<tr>
<td></td>
<td>• Poor feeding</td>
</tr>
<tr>
<td></td>
<td>• Hypotonia(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Abnormal cry–weak or high-pitched(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Seizures</td>
</tr>
<tr>
<td></td>
<td>• Changes in level of consciousness–stupor, coma(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Lethargy(^\text{12}), apathy</td>
</tr>
<tr>
<td>Other</td>
<td>• Apnoea(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Bradycardia</td>
</tr>
<tr>
<td></td>
<td>• Cyanosis</td>
</tr>
<tr>
<td></td>
<td>• Tachypnoea(^\text{12})</td>
</tr>
<tr>
<td></td>
<td>• Hypothermia(^\text{12})</td>
</tr>
</tbody>
</table>
4 Management

Any baby with BGL less than 1.5 mmol/L, or who is symptomatic requires urgent management and further investigation. A staged approach to management and further investigation in the first 48 hours of life is indicated in a hypoglycaemic baby with a BGL greater than or equal to 1.5 mmol/L. If there is suspicion or confirmation of hyperinsulinism or other endocrine or metabolic cause for the hypoglycaemia, manage the baby accordingly. Refer to also Section 6 Persistent hypoglycaemia.

4.1 Prevention

Table 7. Prevention

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation/good practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At birth</strong></td>
<td>• Keep baby warm—maintain temperature 36.5–37.5°C per axilla</td>
</tr>
<tr>
<td></td>
<td>• Early skin to skin contact if appropriate and initiation of feeds within 30–60 minutes of birth—discuss feeding cues with mother</td>
</tr>
<tr>
<td></td>
<td>• Breast feed (preferably) or give expressed breast milk (EBM)</td>
</tr>
<tr>
<td></td>
<td>o Assist woman with colostrum/breastmilk expression</td>
</tr>
<tr>
<td></td>
<td>• Feed at least three hourly or more frequently as baby requires</td>
</tr>
<tr>
<td></td>
<td>• If baby less than 35 weeks admit to neonatal unit</td>
</tr>
<tr>
<td></td>
<td>o Commence gavage feeds if baby unable to demonstrate nutritive sucking/feeding</td>
</tr>
<tr>
<td></td>
<td>• Formula feed if this is maternal choice or with consent if breast milk not available, commence at:</td>
</tr>
<tr>
<td></td>
<td>o If normal or no risk baby (for hypoglycaemia) 30–40 mL/kg/day</td>
</tr>
<tr>
<td></td>
<td>o If at risk baby 60–75 mL/kg/day as tolerated</td>
</tr>
<tr>
<td></td>
<td>• Consider benefits versus disadvantages of giving formula including:</td>
</tr>
<tr>
<td></td>
<td>o Disruption to the establishment and duration of breastfeeding</td>
</tr>
<tr>
<td><strong>Baby less than 35 weeks gestation or low birth weight</strong></td>
<td>• Admit to neonatal unit as per local protocols</td>
</tr>
<tr>
<td></td>
<td>o Contact Retrieval Services Queensland (RSQ) as required</td>
</tr>
<tr>
<td></td>
<td>• Prevent/manage hypothermia</td>
</tr>
<tr>
<td></td>
<td>• If baby’s clinical condition allows, give early and frequent feeds</td>
</tr>
<tr>
<td></td>
<td>• Commence gavage feeds as indicated, e.g. if ineffective breastfeed</td>
</tr>
<tr>
<td></td>
<td>• Manage other conditions as required</td>
</tr>
<tr>
<td><strong>Feeding</strong></td>
<td>• Breastfeed if baby’s condition allows</td>
</tr>
<tr>
<td></td>
<td>o Encourage skin-to-skin contact between mother and baby</td>
</tr>
<tr>
<td></td>
<td>• Assist maternal breast milk expression as required</td>
</tr>
<tr>
<td></td>
<td>o Advise three hourly hand expressing in the first 24 hours until feeding is established</td>
</tr>
<tr>
<td></td>
<td>• If enteral feeding not possible or contraindicated:</td>
</tr>
<tr>
<td></td>
<td>o Commence IV glucose 10% at 60 mL/kg/day [refer to Table 13. IV fluids]—provides 4.2 mg/kg/minute of glucose</td>
</tr>
<tr>
<td></td>
<td>• Complementary feeds of EBM or formula not required in first 24 hours unless:</td>
</tr>
<tr>
<td></td>
<td>o One BGL less than 2 mmol/L OR</td>
</tr>
<tr>
<td></td>
<td>o Two or more BGL are less than 2.6 mmol/L</td>
</tr>
<tr>
<td></td>
<td>• If complementary feed required, give:</td>
</tr>
<tr>
<td></td>
<td>o Minimum 7.5 mL/kg/feed (based on 60 mL/kg/24 hours on day one)</td>
</tr>
<tr>
<td></td>
<td>• If baby breastfeeding well and BGL in normal range halve complementary feeding quota</td>
</tr>
<tr>
<td></td>
<td>• If BGL greater than or equal to 2.6 mmol/L in first 24 hours—continue breastfeeding and cease complementary feeds</td>
</tr>
<tr>
<td><strong>Symptomatic or unwell baby</strong></td>
<td>• If baby becomes symptomatic or unwell:</td>
</tr>
<tr>
<td></td>
<td>o Medical/neonatal nurse practitioner (NNP) review</td>
</tr>
<tr>
<td></td>
<td>o Admit baby to neonatal unit</td>
</tr>
<tr>
<td></td>
<td>▪ Contact RSQ as required</td>
</tr>
<tr>
<td></td>
<td>• Refer to Table 8. Initial management</td>
</tr>
</tbody>
</table>
### 4.2 Initial management (first 48 hours of life)

**Table 8. Initial management (first 48 hours of life)**

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation/good practice point</th>
</tr>
</thead>
</table>
| **Management of well baby (feeding)** | • If BGL 1.5–2.5 mmol/L and baby is greater than or equal to 35+0 weeks gestation, well and feeding  
  o Give glucose gel 40% [refer to Table 9. Glucose gel] and ensure baby has an effective feed  
  o Feed at least three hourly  
  • If BGL less than 1.5 mmol/L admit to neonatal unit and commence glucose 10% IV infusion [refer to Table 13. IV fluids] |
| **BGL 1.5–2.5 mmol/L and poor feeding** | • Give glucose gel 40% and feed baby [refer to Table 9. Glucose gel]  
  • Notify medical officer/NNP  
  • Consider:  
  o Other observations regarding general condition of baby  
  o Referral to lactation consultant  
  o Other investigations [refer to Table 16. Indications for ]  
  • If BGL less than or equal to 2 mmol/L after treatment with glucose gel  
  o Admit to neonatal unit  
  o Commence IV therapy [refer to Table 13. IV fluids]  
  o Continue breastfeeding (if baby able)  
  • If BGL greater than 2 mmol/L and less than or equal to 2.6 mmol/L:  
  o Administer glucose gel 40% [refer to Table 9. Glucose gel]  
  o Feed baby immediately–preferably breastfeed  
  ▪ Give oral or enteral colostrum or EBM, or formula, or a combination  
  ▪ Give 60–90 mL/kg/day (6–9 mL/kg)  
  • If BGL greater than or equal to 2 mmol/L and increasing, continue feeding baby and monitoring BGL  
  • If BGL less than or equal to 2 mmol/L and not increasing, manage as if less than 1.5 mmol/L |
| **BGL less than 1.5 mmol/L or unrecordable** | • Do not delay treatment–admit to neonatal unit  
  • Confirm screening BGL in blood gas machine, enzymatic point of care analyser or laboratory  
  • Collect diagnostic blood and urine samples [refer to Table 17. Tests]  
  • Urgently give IV glucose bolus and commence IV therapy  
  • If IV/UVC access is difficult or delayed more than 10 minutes, administer stat dose of glucagon by IM or subcutaneous injection and contact RSQ for advice regarding cannulation options  
  • Refer to Table 15. Medications and NeoMedQ  
  • Repeat BGL by diagnostic test after 30 minutes of glucose 10% IV infusion commenced or glucagon administered  
  • Hypoglycaemia non-responsive to glucagon may be due to glycogen storage disease  
  • If not contraindicated, continue breastfeeds; or if maternal choice give formula feeds–consider any feeds in total fluid volume |
| **Persistent or suspected long-term hypoglycaemia** | • Continue four to six hourly BGL monitoring and investigate for underlying cause [refer to Table 16. Indications for ] if:  
  o Family history/features of chronic disorder [refer to 2 Babies at risk] OR  
  o BGL not greater than 2.6 mmol/L in first 48 hours OR  
  o Baby is not feeding |
| **Ceasing BGL monitoring** | • Cease BGL monitoring when:  
  o Baby is feeding effectively AND baby looks well AND  
  o BGL is greater than or equal to2.6 mmol/L in the first 48 hours OR  
  o BGL is greater than or equal to 3 mmol/L for three successive measurements  
  • If baby required glucose IV and is now feeding and has not received glucose IV in preceding 12 hours  
  o Check BGL six hourly prefeed and cease monitoring if greater than 3 mmol/L for two successive measurements |
4.3 Glucose gel 40%
In Queensland glucose gel suitable for the management of neonatal hypoglycaemia is supplied, off label for newborn use, as 15 grams of glucose per 37.5 gram tube (Glucose 15®). This is equivalent to 40% glucose. The label states it is an oral preparation but is administered buccally in the newborn baby. Although the label states not to use this preparation in children less than two years of age, it is considered safe and effective for treatment of transient hypoglycaemia in the newborn. It is recommended, to avoid confusion when it is required urgently, that pharmacy departments label ward stock of the gel accordingly and include the dose of 0.5 mL/kg on the label. Also, refer to NeoMedQ https://www.health.qld.gov.au/qcg/neonatal-medicines.

Table 9. Glucose gel

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration/recommendation</th>
</tr>
</thead>
</table>
| **Context**     | • Effective adjunct to oral feeding in the first 48 hours of life during periods of transient hypoglycaemia  
                  • A single buccal dose (200mg/kg) 0.5 mL/kg of glucose 40% gel reduces incidence of hypoglycaemia (RR 0.68; 95% CI 0.47–0.99, p = 0.04)  
                  • Reduces incidence of hypoglycaemia compared with placebo administration (RR 0.79; 95% CI 0.64–0.98, p = 03; NNT = 10, 95% CI 5–115)  
                  • Reduces admission to Neonatal Intensive Care Unit for hypoglycaemia (RR 0.46; 95% CI 0.21–1.01, p = 0.05)  
                  • Treatment with glucose gel does not affect neurosensory outcome at two years of age |
| **Criteria to escalate** | • Notify medical officer or NNP after glucose gel administered if:  
                  o BGL remains less than 2.6 mmol/L  
                  o Baby becomes unwell or is feeding poorly  
                  • Admit to neonatal unit if:  
                  o BGL less than 2.6 mmol/L despite two doses of glucose gel 40% and breastfeed or EBM or formula feed (combined volume of 60mL/kg/day)  
                  o BGL less than 1.5 mmol/L at any time |
| **Repeat doses** | • Consider continuing up to 6 doses (within first 48 hours of life) if:  
                  o Baby’s clinical examination by medical officer or NNP is normal AND  
                  o Baby is asymptomatic AND  
                  o Baby is feeding well AND  
                  o Prefeed BGL is greater than 2 mmol/L AND  
                  o BGL is rising after each glucose gel dose  
                  • If baby has risk factors and requires a third consecutive dose admit to neonatal unit and consider discussing with a neonatologist |
| **Administration** | • To administer:  
                  o Dry baby’s buccal mucosa with gauze  
                  o Rub into buccal mucosa  
                  • Breastfeed baby immediately after administration |
| **Feeding**     | • **Immediate** breast feeding after glucose gel administration improves the quality of subsequent breast feeds  
                  • Breast feeding reduces requirement for repeated glucose gel doses (OR=0.52, 95% CI 0.28–0.94)  
                  • EBM has less effect as an adjunct with glucose gel to maintain the baby’s BGL  
                  • Continue to encourage exclusive breastfeeding if possible, although formula may be required if the BGL is persistently low |

*Refer to an Australian pharmacopoeia for complete drug information
4.3.1 Glucose gel doses
For dosing based on baby’s weight refer to Appendix B Glucose 40% gel doses

Table 10. Glucose gel regimen

<table>
<thead>
<tr>
<th>BGL level</th>
<th>Glucose gel dose</th>
<th>Good practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 1.5 mmol/L at any time</td>
<td>Nil or any doses</td>
<td>• If possible, give glucose gel 40% and feed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Admit baby to neonatal unit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Commence IV glucose [refer to Table 13. IV fluids]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider other management [refer to Table 11. BGL measurement]</td>
</tr>
<tr>
<td>1.5–2.5 mmol/L</td>
<td>Administer dose</td>
<td>• Give 0.5 mL/kg of glucose gel 40% (200 mg/kg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Breast feed baby or give 60mL/kg of formula, EBM or a combination</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Repeat BGL 30 minutes after dose</td>
</tr>
<tr>
<td>2–2.5 mmol/L</td>
<td>After first dose</td>
<td>• Repeat glucose gel 40% dose (200 mg/kg) followed by a feed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess and check baby’s feeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Repeat BGL 30 minutes after dose</td>
</tr>
<tr>
<td>2–2.5 mmol/L</td>
<td>After second dose</td>
<td>• Repeat glucose gel 40% dose (200 mg/kg) up to 6 doses in 24 hours—no more than 2 doses in succession, each time followed by a feed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If two doses given and/or six doses in 24 hours manage as for baby with BGL less than or equal to 1.5 mmol/L</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess and check baby’s feeding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Repeat BGL 30 minutes after dose</td>
</tr>
<tr>
<td>Less than 2 mmol/L</td>
<td>After second dose</td>
<td>• Admit baby to neonatal unit for IV glucose [refer to Table 13. IV fluids]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Feed baby as indicated and able</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Maintain baby’s temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess for any other signs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider the nature of the baby’s risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider other management [refer to Table 11. BGL measurement]</td>
</tr>
</tbody>
</table>
4.4 Ongoing management

If glucose infusion rate (GIR) greater than 8 mg/kg/minute, consider administering glucagon infusion to minimise interference with the establishment of breast feeding, avoid fluid overload and lessen pancreatic over stimulation with high glucose delivery. Consult with a neonatologist for advice regarding management and investigations by contacting RSQ.

4.4.1 BGL monitoring

Table 11. BGL measurement

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation/good practice point</th>
</tr>
</thead>
</table>
| BGL    | • Measure:  
|        |   - Hourly until greater than or equal to 2.6 mmol/L, then every 4–6 hours prefeed  
|        |   - 30 minutes after any changes to concentration or volume of IV glucose administered to confirm response  
|        | • Optimal BGL\(^4\):  
|        |   - Greater than or equal to 2.6 mmol/L in first 24 hours  
|        |   - Greater than or equal to 3.3 mmol/L after 48 hours or as advised by neonatologist or paediatric endocrinologist\(^4\)  
|        |   - Greater than or equal to 4 mmol/L for suspected or known persistent hypoglycaemic disorder (e.g. endocrine or metabolic disorder) at any time  
|        | • If greater than or equal to 3 mmol/L for 12 hours on first day of life or greater than or equal to 4 mmol/L on second day:  
|        |   - Gradually reduce IV glucose as enteral feeds increase  
|        |     ▪ If GIR is greater than or equal to 8 mg/kg/minute, reduce the infusion by 2 mg/kg/minute every six hours  
|        |     ▪ If GIR is less than 8 mg/kg/minute weaning may be quicker  
|        | • Before and during weaning continue to monitor BGL and consider:  
|        |   - Glucose concentration and volume of fluid being infused (mL/kg/day)  
|        |   - How well the baby’s feeding is being established  
|        |   - Medications the baby is receiving to treat hypoglycaemia  
|        |     ▪ If IV glucagon infusion is used, wean when full feeds achieved  
|        |     ▪ If hydrocortisone is used, wean when full feeds achieved and glucagon is ceased  
| Cease BGL monitoring | • Cease BGL monitoring if:  
|        |   - Full feeds achieved and BGL consistently greater than or equal to 3 mmol/L (first day) or greater than or equal to 4 mmol/L after first day  
|        |   - Complementary feeds or IV glucose not required and BGL now greater than or equal to 2.6 mmol/L for 24 hours (within first 48 hours) or  
|        |   - Complementary feeds and/or IV glucose were required and now ceased, and BGL now greater than or equal to 2.6 mmol/L prior to three consecutive normal feeds (within first 48 hours)  

Refer to online version, destroy printed copies after use
### 4.4.2 Other management

#### Table 12. Ongoing management

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation/good practice point</th>
</tr>
</thead>
</table>
| Fluid management                | - If required, increase volume of fluid administered  
  - An increase of 20 ml/kg/day (from 60 mL/kg/day to 80 mL/kg/day) provides a 33% increase in glucose  
  - Check sodium level—if low prepare a solution with increased glucose concentration for equivalent glucose delivery rate, or commence or increase glucagon infusion and reduce fluid intake  
  - Refer to Table 13. IV fluids and Appendix C Glucose infusion rates (GIR)  
  - Increase the concentration of glucose to 12% or step-wise to higher concentration as required [refer to Appendix C Glucose infusion rates (GIR)]  
  - Glucose 12% provides a 20% increase in glucose  
  - If the required IV infusion concentration is greater than 12% insert umbilical venous catheter (UVC) or central line  
  - If required increase volume to 100 mL/kg/day maximum in first 24 hours46  
  - Consider risk of fluid overload  
  - Review serum sodium and other electrolyte levels regularly  
  - If not contraindicated, continue feeds and include these in the fluid calculation |
| Further investigations and management | - Further investigations for cause of hypoglycaemia may be required  
  - Refer to Table 16. Indications for  
  - Consider further investigations and pharmacological intervention⁶ if:  
  - IV glucose rate greater than or equal to 8 mg/kg/minute, OR  
  - Baby is more than 48 hours of age, OR  
  - Baby presents with hypoglycaemia for the first time after 24 hours, OR  
  - BGL is difficult to control [refer to Table 15. Medications] |
### 4.5 Intravenous glucose

Consider administering glucose gel 40% buccally while admitting baby to neonatal unit and inserting intravenous cannula. Refer to Table 9. Glucose gel.

<table>
<thead>
<tr>
<th>Table 13. IV fluids</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aspect</strong></td>
</tr>
</tbody>
</table>
| **Indications** | • Baby with risk factors for hypoglycaemia who is not feeding [refer to 2. Babies at risk]  
• Breastfeeding baby when formula is indicated but consent is withheld  
• BGL less than 1.5 mmol/L or unrecordable and/or any signs consistent with severe hypoglycaemia |
| **Escalation points** | • If greater than 12% glucose required administer via central catheter–umbilical vein catheter or peripherally inserted central catheter (PICC)If IV access delayed, administer glucagon by intramuscular or subcutaneous injection [refer to Table 15. Medications]  
• Discuss baby’s management with neonatologist via RSQ if:  
  o Frequent or prolonged hypoglycaemia [refer to Table 19. Ongoing long term management]  
  o Glucose infusion concentration is greater than 14 % or GIR is greater than 8 mg/kg/minute  
  o Glucagon or hydrocortisone required |
| **Bolus dose** | • Not required for baby who only has risk factors or has mild, transient hypoglycaemia (BGL greater than 1.5 mmol/L in first 48 hours of life) and is feeding  
• Use bolus doses of glucose sparingly except where severe or symptomatic hypoglycaemia  
• Urgently–slowly administer glucose 10% IV 1–2mL/kg (100–200 mg/kg) as bolus dose increase IV glucose infusion rate  
  o Use clinical judgement regarding the severity of the hypoglycaemia and consider risk of rebound hypoglycaemia  
• Repeat BGL after 30 minutes and if indicated repeat dose at 1 mL/kg |
### 4.5.1 Regimen for glucose infusion

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation/good practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Table 14. Regimen for glucose infusion</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **Commencement** | • Commence glucose 10% IV infusion at 60 mL/kg to give 4.2 mg/kg/minute of glucose  
• Calculate IV glucose in mg/kg/minute [refer to Appendix C Glucose infusion rates (GIR)]  
• Baby with hyperinsulinaemia may require higher glucose concentration³  
• Baby requiring high glucose concentration may have hyperinsulinism  
• Baby with endocrine deficiency or inborn error of metabolism more likely to require only 4–6 mg/kg/minute of glucose to maintain euglycaemia |
| **Severe or persistent hypoglycaemia** | • As required:  
  o If severe or persistent hypoglycaemia increase the fluid volume before the concentration as this will result in an immediate change in glucose delivery rate  
  o Increase IV glucose in 20 mL/kg/day increments (e.g. 60 mL/kg/day to 80 mL/kg/day)–a temporary increase in volume may be required while solution of increased glucose concentration is prepared  
  o Administer glucagon [refer to Table 15. Medications]  
  • Increase IV glucose concentration to 12 % or step-wise to a higher concentration²⁴ [refer to Appendix D Preparing glucose concentrations for infusion]  
  • If baby is less than 24 hours of age, 100 mL/kg/day total fluid intake is maximum most babies are likely to tolerate without developing fluid overload (some babies may develop hyponatraemia at lower infusion rates)  
    o Consider higher glucose concentration and commencing glucagon infusion |
| **Hyponatraemia risk** | • If hyponatraemic or fluids greater than or equal to 100mL/kg/day (especially in first 24 hours of life):  
  o Consider risk of fluid overload [refer to Table 11. BGL measurement]  
  o Insert central access line (as soon as possible when time allows), for administration of increased concentration and reduced fluid volume  
  o Consider commencing glucagon infusion and/or  
  o Administer hydrocortisone–may be preferred option if laboratory or clinical evidence suggesting hypoadrenalism or if insufficient response to glucagon, or baby is also hypotensive  
    o If not contraindicated, continue oral feeds  
  • Review serum sodium levels regularly |
| **Weaning** | • General principles of weaning treatment:  
  o Wean IV glucose and increase to full feeds (appropriate for day of age), then  
  o Wean glucagon (if used), then  
  o Wean hydrocortisone (if used)  
    ▪ If hyperinsulinaemia is the cause of hypoglycaemia, consider weaning hydrocortisone earlier to avoid adrenal suppression–discuss with paediatric endocrinologist  
  • If difficult weaning, consult with neonatologist via RSQ for further discussion with paediatric endocrinologist or metabolic specialist as indicated |
### 5 Medications

If BGL does not normalise after buccal glucose gel 40% [refer to Table 9. Glucose gel] or IV glucose consider other medication(s) to manage hypoglycaemia. Take blood samples immediately before commencing medications while the baby is hypoglycaemic. Consider discussion with a neonatologist paediatric endocrinologist or paediatric metabolic physician by contacting RSQ.


#### Table 15. Medications

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
• Indicated for babies with refractory hypoglycaemia when liver glycogen stores are available (as increases gluconeogenesis and glycogenolysis)16  
• Effective for babies of women with diabetes or other hyperinsulinaemic conditions proven to be refractory to intravenous glucose infusion  
• May be less likely to be effective in FGR babies (due to lower glycogen stores)–although many do respond  
• If IV access delayed or difficult may be given by IM or subcutaneous injection  
• Blood glucose level should rise within one hour of commencing infusion and lasts approximately two hours50–commence concomitant intravenous glucose infusion to avoid rebound hypoglycaemia |
• Reduces peripheral glucose utilisation and increases gluconeogenesis  
• Has a slower response than glucagon |
• Potassium channel activator that inhibits insulin release from the pancreas  
• If persistent hypoglycaemia use to wean from glucose infusion and for long-term management |
• Diuretic given in conjunction with diazoxide  
• Inhibits pancreatic release of insulin |
• Hyperinsulinaemic hypoglycaemia is known or suspected  
  o Not usually commenced in the newborn period–consult with paediatric endocrinologist |

*Refer to an Australian pharmacopoeia for complete drug information
6 Persistent hypoglycaemia
Hypoglycaemia persisting beyond 48 hours requires further investigation and management.

6.1 Further investigation and management

Table 16. Indications for investigations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Context**             | • Investigation and management are required for severe, persistent, recurrent or atypical hypoglycaemia\(^3,15,31\)  
  • Investigate the underlying mechanism for the hypoglycaemia to identify specific treatment requirements\(^4\) [refer to Table 17. Tests]  
  • If further investigations are required early discussion with a neonatologist is indicated to advise:  
    o Regarding paediatric endocrinology consultation  
    o Need for retrieval to a tertiary neonatal unit |
| **Presentation**        | • Symptomatic hypoglycaemia\(^15,30\) or need for glucose IV to treat after 48 hours of age\(^6,15\)  
  • Seizures or altered level of consciousness  
  • Inability to consistently maintain pre-prandial BGL:  
    o Greater than 2.6 mmol/L up to 48 hours of age or 3.3 mmol/L beyond first 48 hours OR  
    o If known hypoglycaemia, condition 4 mmol/L after 48 hours\(^66\)  
  • Unusual presentation of hypoglycaemia or baby with no known risk factors |
| **Severe hypoglycaemia**| • If not a baby of a woman with diabetes, low BGL (less than 1.5 mmol/L in first 6 hours of life)  
  • Persistent or recurrent hypoglycaemia despite glucose IV greater than or equal to 8 mg/kg/minute\(^67\)  
  • Required treatment with medication |
| **Late hypoglycaemia**  | • BGL less than 2.6 mmol/L onset after 24 hours of life  
  • Early onset persistent or any hypoglycaemia recurrent after 48 hours |
| **Family history**      | • Genetic hypoglycaemia  
  • Inborn errors of metabolism in parent or sibling, (e.g. MCADD\(^18\), LCHAD or other fatty acid oxidation defect)  
  • Endocrine disorders  
  • Sudden infant death syndrome\(^30\)  
  • Reye’s syndrome\(^30\)  
  • Developmental delay\(^30\) |
| **Abnormalities**       | • Presence of associated abnormalities (e.g. midline facial malformations, microcephalus; exomphalos)\(^30\) |
### 6.2 Pathology tests

#### Table 17. Tests

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Blood$^{3,4,6}$ | - Take venous or arterial samples only  
- Identify *Neonatal Hypoglycaemia* on the request form and ask for urgent testing by pathology service  
- Advise limited volume of blood available for testing  
- Don’t allow blood specimen to haemolyse as this may lead to an artificially low insulin level$^{68}$  
- Take blood specimens immediately **before** treatment while baby is hypoglycaemic |
| Priority | Specimen |
| 1 | - Blood gas syringe or capillary tube—blood gas, lactate, glucose, electrolytes, haemoglobin, haematocrit  
- Serum (red pedi-pot) 0.5 mL for cortisol and insulin  
- Lithium heparin (green pedi-pot) 0.5 mL for acylcarnitine profile or separate/additional neonatal screening card |
| 2 | - Serum (red pedi-pot) 0.5 mL for growth hormone |
| 3 | - Lithium heparin (green pedi-pot) 0.5 mL for plasma amino acids  
- EDTA$^*$ (purple pedi-pot) 0.5 mL for ammonium—notify and send to laboratory urgently  
- Serum (red pedi-pot) 1 mL for electrolytes and liver function tests (LFTs) **OR** 0.5 mL for LFTs only  
- Pyruvate (tube from laboratory) 0.5 mL for pyruvate  
- Serum (red pedi-pot) 0.4 mL for beta hydroxybutyrate |
| Urine | - Metabolic screen  
  o First sample **after** hypoglycaemic episode  
  o Do not wait to start treatment while collecting sample  
  o Collect 10mL if possible (send available volume from one sample only) |

*$^*EDTA$–Ethylenediaminetetraacetic acid*
6.3 Interpretation of investigations

Conditions causing hypoglycaemia may occur concurrently, (e.g. hyperinsulinaemia with low cortisol due to prematurity or hyperinsulinaemia and low cortisol and low growth hormone due to pituitary disorder).

Table 18. Investigations interpretation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Hyper-insulinaemic state** | • Occurs when there is detectable insulin when baby is hypoglycaemic  
  • Confirmed by low levels or absence of free fatty acids (less than 1 mmol/L) and beta hydroxy-butyrate (less than 1.8 mmol/L)  
  • Usually transient but may be persistent and require long-term treatment  
  • In absence of maternal diabetes, consult with neonatologist via RSQ for paediatric endocrinologist advice |
| **Cortisol** | • If more than 200 nmol/L—likely to be a normal response  
  ° May be blunted in preterm baby, hyperinsulinism or prolonged hypoglycaemia of any cause  
  • If lesser response—suggestive of hypothalamic, pituitary or adrenal dysfunction  
  ° Consult urgently with neonatologist via RSQ for paediatric endocrinologist advice |
| **Growth hormone** | • Test has good sensitivity but relatively poor specificity  
  • Greater than or equal to 7 micrograms per litre (20 mIU/L)—normal response during hypoglycaemia in term baby (may be blunted in preterm baby)  
  • If lesser response—may be suggestive of hypothalamic or pituitary dysfunction  
  ° Consult urgently with neonatologist via RSQ for paediatric endocrinologist advice |
| **Ammonia** | • If greater than 100 micromol/L consider metabolic disorder (e.g. urea cycle defect) or hyperinsulinaemia hyperammonaemia syndrome  
  ° Consult urgently with neonatologist via RSQ for paediatric metabolic specialist advice |

| **Severe/persistent/recurrent hypoglycaemia** | **Refer to Table 19. Ongoing long term management**  
  • If endocrine disorder not identified—consult urgently with neonatologist via RSQ for paediatric endocrinologist and/or metabolic specialist advice |

6.4 Long term management

Table 19. Ongoing long term management

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Consultation** | • Consult with neonatologist via RSQ for advice from paediatric endocrinologist, metabolic specialist or both  
  • If hypoglycaemia:  
  ° Severe (less than 1.5 mmol/L), recurrent (more than three sequential episodes of BGL less than 2.6 mmol/L) or prolonged or lasts longer than 48 hours |
| **Severe or persistent hypoglycaemia** | • Endocrine or metabolic conditions that predispose to persistent hypoglycaemia may first present as transient neonatal hypoglycaemia, e.g. hypopituitism and settle  
  • Persistent hypoglycaemic conditions may result in neurological damage if:  
  ° Mild but recurrent hypoglycaemia or  
  ° Feeds are delayed or interrupted (e.g. due to recurrent illness)  
  • Exclude persistent or prolonged hypoglycaemic conditions  
  ° Persistent hyperinsulinaemic conditions—if low level of ketones present the risk is increased  
  ° Endocrine deficiencies, for example hypopituitarism and hypoadrenalism  
  ° Inborn errors of metabolism, e.g. fatty acid oxidation defects |
| **Fasting test** | • Prior to discharge [refer to Table 20. Six hour fast test] |
### 6.5 Six hour fast test
Prior to commencing the six hour fast test consult with a neonatologist via RSQ for advice (may include input from a paediatric endocrinologist or metabolic specialist).

#### Table 20. Six hour fast test

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Context** |  • Six hours duration unless otherwise recommended by endocrinologist or metabolic specialist  
• Identifies baby requiring additional investigation or management⁴  
• If baby has known prolonged or persistent hypoglycaemic disorder (e.g. hyperinsulinaemia, or has had clinically significant hypoglycaemia test ensures baby can maintain normoglycaemia (in a fasted state after discharge))⁴  
• Test is conducted on discharge medications (e.g. diazoxide and hydrochlorothiazide) if these have been recommended  |
| **Indications** |  • Family history of hypoglycaemia or congenital anomalies suggestive of pituitary or adrenal disorder to screen for persistent hypoglycaemic disorder despite normal previous BGLs  
• History of clinically significant hypoglycaemia to identify a baby who requires testing for a persistent disorder  
  o Baby required IV glucose greater than 6 mg/kg/minute or medication to maintain normoglycaemia-  |
| **BGL** |  • Check at four, five and six hours post feed (omit further feeds during test)  
• If known family history or congenital anomaly–BGL target is greater than or equal to 4 mmol/L  
• If history of clinically significant hypoglycaemia–BGL target is above 3.3 mmol/L⁷  |
| **Actions** |  • If BGL less than 3 mmol/L at any time  
  o Perform investigations as to the cause and then feed baby  
  o Continue BGL monitoring  
  o Delay discharge of baby  
  o Consult with neonatologist via RSQ for advice from paediatric endocrinologist or metabolic specialist  
• If baby symptomatic between scheduled BGL measures  
  o Check BGL early  
    • If low–perform investigations and then feed baby  
• If baby asymptomatic and BGL greater than or equal to 3 mmol/L throughout–finish test and feed baby  
• If BGL less than 4 mmol/L baby requires further assessment and management before discharge  
  o Consult with paediatric endocrinologist  
• Continue prefeed BGL monitoring  |
# 7 Sequelae of hypoglycaemia

Table 21. Sequelae

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context                       | • Both **symptomatic** and **asymptomatic** hypoglycaemia may lead to adverse neurodevelopment outcome when compared with euglycaemic babies\(^{71}\)  
  • Magnetic resonance imaging:  
    o As requested by neonatologist, or paediatric endocrinologist or metabolic specialist  
    o Occasionally useful to assist with prognosis or rule out other pathology                                                                  |
| Neuro-developmental outcome   | • Cognitive impairment more likely than motor impairment\(^{72}\)  
  • May present in neonatal period as encephalopathy with\(^{73}\):  
    o Poor feeding  
    o Lethargy  
    o Seizures  
    o Hypothermia  
    o Respiratory distress  
  • Hypoglycaemic encephalopathy:  
    o Usually injury to posterior region of brain typically the occipital cortex\(^{73}\) or parietal lobes\(^{72}\)  
    o Develops in white matter\(^{72}\)  
    o May follow neonatal focal or generalised seizures resulting from symptomatic hypoglycaemia\(^{21}\)  
  • Potential short and long-term sequelae include:  
    o Head growth suboptimal consistent with white matter injury\(^{72}\) intellectual disability, learning difficulties, behavioural difficulties\(^{21}\), visual co-ordination  
    o Hemiplegic cerebral palsy or spastic quadriplegia; milder motor problems\(^{21}\)  
    o Visual impairment\(^{21}\) |
### 8 Discharge planning

Table 22. Discharge planning

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Discharge planning**                               | • Consider six hour fast with BGL monitoring to exclude:  
  o Persistent hyperinsulinaemic conditions  
  o Endocrine deficiencies  
  o Inborn errors of metabolism⁴,⁶  
  o Hypoglycaemia despite medication (e.g. diazoxide and hydrochlorothiazide) prescribed for discharge  
  o Refer to Table 20. Six hour fast test  
  • If in doubt, discuss with neonatologist, paediatric endocrinologist or metabolic specialist |
| **Discharge criteria**                                | • Baby less than 48 hours of age and pre-prandial BGL is greater than 2.6 mmol/L for three feed-fast cycles [refer to Table 11. BGL measurement]  
  • If known hypoglycaemic condition and baby more than or equal to 48 hours of age and pre-prandial BGL is greater than 4 mmol/L for three feed-fast cycles⁷  
  • Six hour fast test performed (if indicated) and baby able to maintain BGL |
| **Parent education**                                  | • Discuss causes, risks, potential sequelae and management  
  • Include signs that require escalation and the escalation plan  
  • Provide parent information brochure |
| **Follow-up**                                         | • Usual follow-up with general practitioner and child health nurse  
  • If symptomatic, severe, recurrent or atypical hypoglycaemia including:  
  o Follow up by paediatrician or neonatologist  
  o Endocrinologist or metabolic specialist follow-up as indicated  
  • Arrange other follow up as per local protocols |
| **Reducing risk in subsequent pregnancies**           | • Maternal lifestyle—healthy weight and diet management  
  • Genetic counselling/family history  
  • Glycaemic/diabetes management  
  • Refer to Queensland Clinical Guideline *Gestational diabetes*⁷⁴ |
References


Appendix A Growth charts examples

Growth chart for girls

Curves equal the WHO Growth Standard at 50 weeks.

Sources: Intrauterine section - Germany (Vigot 2010), United States (Coben 2010), Australia (Roberts 1990), Canada (Kramer 2001), Scotland (Benecke 2003), and Italy (Bernete 2013). Post-term section - the World Health Organization Growth Standard, 2005.

www.ucalgary.ca/fenton

Date:
Gestational age (weeks)
Growth chart for boys

Curves equal the WHO Growth Standard at 50 weeks.


www.ucalgary.ca/fenton

Refer to online version, destroy printed copies after use
### Appendix B Glucose 40% gel doses

<table>
<thead>
<tr>
<th>Baby's weight (g)</th>
<th>Dose of glucose 40% gel 0.5mL/kg (200 mg/kg) for buccal administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000–2080</td>
<td>1 mL</td>
</tr>
<tr>
<td>2081–2280</td>
<td>1.1 mL</td>
</tr>
<tr>
<td>2281–2480</td>
<td>1.2 mL</td>
</tr>
<tr>
<td>2481–2680</td>
<td>1.3 mL</td>
</tr>
<tr>
<td>2681–2880</td>
<td>1.4 mL</td>
</tr>
<tr>
<td>2881–3080</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>3081–3280</td>
<td>1.6 mL</td>
</tr>
<tr>
<td>3281–3480</td>
<td>1.7 mL</td>
</tr>
<tr>
<td>3481–3680</td>
<td>1.8 mL</td>
</tr>
<tr>
<td>3681–3880</td>
<td>1.9 mL</td>
</tr>
<tr>
<td>3881–4080</td>
<td>2.0 mL</td>
</tr>
<tr>
<td>4081–4280</td>
<td>2.1 mL</td>
</tr>
<tr>
<td>4281–4480</td>
<td>2.2 mL</td>
</tr>
<tr>
<td>4481–4680</td>
<td>2.3 mL</td>
</tr>
<tr>
<td>4681–4880</td>
<td>2.4 mL</td>
</tr>
<tr>
<td>4881–5080</td>
<td>2.5 mL</td>
</tr>
</tbody>
</table>
Appendix C Glucose infusion rates (GIR)

How to calculate GIR (mg/kg/minute) when mL/hour are known (method 1)*

\[
\text{GIR (mg/kg/minute)} = \frac{\% \text{ glucose being infused} \times \text{rate of infusion (mL/hour)}}{\text{Weight} \times 6}
\]

Example–GIR for 4.5 kg baby having 18.75 mL/hour of 12 % glucose

\[
\text{GIR (mg/kg/minute)} = \frac{12\% \times 18.75 \text{ mL/hour}}{4.5 \text{ kg} \times 6} = 8.34 \text{ mg/kg/minute}
\]

OR

How to calculate GIR (mg/kg/minute) when mL/hour are known (method 2)*

\[
\text{GIR (mg/kg/minute)} = \frac{\% \text{ glucose being infused} \times \text{rate of infusion (mL/kg/day)}}{144}
\]

Example–GIR for 4.5 kg baby having 100mL/kg/day of 12 % glucose

\[
\text{GIR (mg/kg/minute)} = \frac{12\% \times 100 \text{ mL/kg/day}}{144} = 8.34 \text{ mg/kg/minute}
\]

GIR quick reference for commonly used concentrations*

<table>
<thead>
<tr>
<th>%</th>
<th>Glucose mg/kg/minute</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mL/kg/day</td>
</tr>
<tr>
<td>10</td>
<td>4.2</td>
</tr>
<tr>
<td>12</td>
<td>5.2</td>
</tr>
<tr>
<td>12.5</td>
<td>5.2</td>
</tr>
<tr>
<td>14</td>
<td>5.8</td>
</tr>
<tr>
<td>15</td>
<td>6.25</td>
</tr>
<tr>
<td>16</td>
<td>6.7</td>
</tr>
<tr>
<td>18</td>
<td>7.5</td>
</tr>
<tr>
<td>20</td>
<td>8.3</td>
</tr>
</tbody>
</table>

*Subtract any other infusions or calculate separately if they contain other concentrations of glucose
Appendix D Preparing glucose concentrations for infusion

How to prepare increased concentrations of glucose

<table>
<thead>
<tr>
<th>Glucose concentration required</th>
<th>Glucose 10% volume (100 mg/mL)</th>
<th>Glucose 50% volume (500mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12%</td>
<td>95 mL</td>
<td>5 mL</td>
</tr>
<tr>
<td>12.5%</td>
<td>93.75 mL</td>
<td>6.25 mL</td>
</tr>
<tr>
<td>14%</td>
<td>90 mL</td>
<td>10 mL</td>
</tr>
<tr>
<td>15%</td>
<td>87.5 mL</td>
<td>12.5 mL</td>
</tr>
<tr>
<td>16%</td>
<td>85 mL</td>
<td>15 mL</td>
</tr>
<tr>
<td>18%</td>
<td>80 mL</td>
<td>20 mL</td>
</tr>
<tr>
<td>20%</td>
<td>75 mL</td>
<td>25 mL</td>
</tr>
</tbody>
</table>

How to calculate increased concentrations of glucose

Formula to increase concentration of 10% glucose and make a 100 mL solution

\[
\text{Stap 1. Volume of high concentration mL} = \frac{\text{total volume mL} \times (\text{desired concentration}\% - \text{lower concentration}\%)}{(\text{high concentration}\% - \text{lower concentration}\%)}
\]

\[
\text{Step 2. Volume of low concentration mL} = \text{desired volume mL} - \text{high concentration volume mL}
\]

\[
\text{Step 3. Volume of desired concentration mL} = \text{high concentration mL} + \text{low concentration mL}
\]

Example—to prepare 100 mL of 12% glucose for infusion

\[
\text{Step 1. Volume of high concentration mL} = \frac{100 \text{ mL} \times (12\% - 10\%)}{(50\% - 10\%)} = \frac{200}{40} = 5 \text{ mL}
\]

\[
\text{Step 2. Volume of low concentration mL} = 100 \text{ mL} - 5 \text{ mL} = 95 \text{ mL}
\]

\[
\text{Step 3. 100 mL} = 5 \text{ mL (50\%)} + 95 \text{ mL (10\%)}
\]

Notes:
- Glucose 50% contains 50 grams per 100 mL or 0.5 grams (or 500 mg) per 1 mL
- Glucose 10% contains 10 grams per 100 mL or 0.1 grams (or 100 mg) per 1 mL
- Rounding final volumes of each concentration of glucose up and down may be required for practical purposes
- Remove the volume equivalent to the 50% glucose to be added from the bag of 10% glucose before adding the 50% glucose solution.
## Appendix E Investigations for neonatal hypoglycaemia

<table>
<thead>
<tr>
<th>Blood samples</th>
<th>Priority</th>
<th>Volume*</th>
<th>Container guide*</th>
<th>Specimen collection during hypoglycaemic episode before treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin, Cortisol</td>
<td>1</td>
<td>0.5 mL</td>
<td>Red cap (serum no gel)</td>
<td><em>If high haematocrit (&gt; 0.55 %)–collect additional tube-answer: Blood samples is one of the blood samples.</em>*</td>
</tr>
<tr>
<td>Lactate, Glucose</td>
<td>1</td>
<td>0.6 mL</td>
<td>Grey cap (fluoro-oxalate)</td>
<td><em>Can be measured on blood gas analyser when performing blood gas-answer: Blood samples is one of the blood samples.</em>*</td>
</tr>
<tr>
<td>Acyl-carnitine profile</td>
<td>1</td>
<td>1–2 filled spots</td>
<td>Newborn screening card</td>
<td><strong>Label card Acyl-carnitine profile-answer: Blood samples is one of the blood samples.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 mL</td>
<td>Green cap (lithium heparin)</td>
<td>In addition to newborn screening test (NST)–send routine NST as usual-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Blood gas including:</td>
<td>1 (or 3)</td>
<td>0.5 mL</td>
<td>Blood gas syringe or capillary tube OR Red cap (serum no gel)</td>
<td>Can be done with blood gas, lactate and glucose if done in blood gas machine as priority 1-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Electrolytes, Haemoglobin, Haematocrit</td>
<td>1 (or 3)</td>
<td>0.5 mL</td>
<td>Red cap (serum no gel)</td>
<td>Send specimen on ice to laboratory to prevent metabolism of glucose by red cells on route-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td></td>
<td>1 (or 3)</td>
<td>0.5 mL</td>
<td>Red cap (serum no gel)</td>
<td>Priority 3 if not done in blood gas machine-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Electrolytes/liver function tests</td>
<td>3</td>
<td>1 mL</td>
<td>Red cap (serum no gel)</td>
<td>If liver function tests only collect 0.5 mL-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Growth hormone</td>
<td>2</td>
<td>0.5 mL</td>
<td>Red cap (serum no gel)</td>
<td>On ice, preferably less than 1 hour to the laboratory-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Beta hydroxybutyrate</td>
<td>3</td>
<td>0.4 mL</td>
<td>Red cap (serum no gel)</td>
<td>-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Adrenocorticotropic hormone</td>
<td>As advised</td>
<td>0.4 mL</td>
<td>Pink/purple cap (EDTA*)</td>
<td>-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Plasma amino acid profile</td>
<td>3</td>
<td>0.5 mL</td>
<td>Green cap (lithium heparin)</td>
<td>-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Ammonium</td>
<td>3</td>
<td>0.5 mL</td>
<td>Pink/purple cap (EDTA*)</td>
<td>Notify laboratory and send urgently. If any delay put on ice-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Pyruvate</td>
<td>3</td>
<td>0.5 mL</td>
<td>Yellow lid specimen container</td>
<td>Contact pathology service prior to collection for perchlorate tube-answer: Blood samples is one of the blood samples.**</td>
</tr>
<tr>
<td>Urine sample</td>
<td></td>
<td>10 mL (or available volume from one sample)</td>
<td>Yellow lid specimen container</td>
<td>Treatment can start while collecting specimen-store and transport at 4 °C-answer: Blood samples is one of the blood samples.**</td>
</tr>
</tbody>
</table>

*EDTA—Ethylenediaminetetraacetic acid (anticoagulant used in blood collection)
Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads

Ms Karen Hose, Nurse Practitioner, Royal Brisbane and Women's Hospital
Professor Helen Liley, Neonatologist, Mater Mother's Hospital, Brisbane

QCG Program Officer

Ms Stephanie Sutherns

Working Party Members

Dr Gary Alcock, Neonatologist, The Townsville Hospital
Mrs Seija Argyros, Neonatal Nurse Practitioner, Royal Brisbane and Women's Hospital
Mrs Maxine Ballinger, Clinical Nurse Consultant, Rockhampton Hospital
Miss Chase Becker, Clinical Nurse/Midwife, Amana Hospital/Midwife Vision Global/Royal Adelaide Hospital
Ms Jan Becker, Clinical Nurse/Registered Midwife, Amana Hospital/Midwife Vision Global
Mrs Katie Cameron, Consumer Representative, Maternity Consumer Network
Dr David Cartwright, Neonatologist, Royal Brisbane and Women's Hospital
Ms Nicole Chappell, Registered Midwife/Registered Nurse, Logan Hospital
Associate Professor Louise Conwell, Paediatric Endocrinologist, Queensland Children's Hospital
Dr Mark Davies, Neonatologist, Royal Brisbane and Women's Hospital
Mrs Carole Dodd, Registered Midwife/Clinical Nurse, Caboolture Hospital
Dr Joy Domingo-Bates, Neonatal Fellow, Mater Mother's Hospital/Royal Brisbane and Women's Hospital
Dr Christopher Edwards, General Paediatrician, Bundaberg Base Hospital
Miss Isabelle Fassbind, Pharmacist, Royal Brisbane and Women's Hospital
Mrs Andreena Flint, Neonatal Nurse Practitioner, Redcliffe Hospital
Mrs Nicol Franz, Registered Nurse, Caboolture Hospital
Dr Jessica Gaughan, Senior Medical Officer and Rural Generalist, Emerald Hospital
Dr Leigh Grant, Obstetrician and Gynaecologist, Rockhampton Hospital
Mrs Linda Hackett, Clinical Nurse, Bundaberg Hospital
Mrs Marmina Hales, Registered Nurse/Registered Midwife, Logan Hospital
Ms Julia Hannan, Registered Nurse/Registered Midwife, Sunshine Coast University Hospital
Professor Jane Harding, Professor of Neonatology, The University of Auckland, New Zealand
Dr Shivanand Hebbandi, Paediatrician, Redland Hospital
Mrs Julianne Hite, Clinical Nurse/Neonatal Nurse Educator, Rockhampton Hospital
Mrs Anne Illingsworth, Clinical Nurse Consultant, The Townsville Hospital
Mrs Helen Kross, Clinical Nurse/Midwife, Ayr Health Service
Miss Christine Latimer, Clinical Nurse Consultant, The Townsville Hospital
Ms Amanda Merchant, Clinical Nurse Consultant, Mater Mother’s Hospital
Ms Debbie Mitchell, Midwifery Educator/Baby Friendly Health Initiative Co-ordinator, Emerald Hospital
Dr Parvin Ninkafs, Registered Midwife, Gold Coast University Hospital
Ms Jacqueline O'Neill, Midwife, Toowoomba Base Hospital
Ms Marian Rigney, Associate Nurse Unit Manager, Redland Hospital
Ms Teresa Sander, Registered Midwife, Rockhampton Hospital
Dr Sonia Shah, Paediatrician, Buderim Private Hospital
Ms Linda Thomasson, Clinical Midwife/Lactation Consultant, Bundaberg Hospital
Dr Lizelle Weber, Director of Neonatology, Sunshine Coast University Hospital
Ms Louise Wilkins, Lactation Consultant, Logan Hospital
Ms Amanda Wolski, Registered Midwife, Logan Hospital

Queensland Clinical Guidelines Team

Associate Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Ms Emily Holmes, Clinical Nurse Consultant
Dr Brent Knack, Program Officer

Steering Committee

Funding

This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health